{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:10:29Z","timestamp":1784268629156,"version":"3.55.0"},"reference-count":4,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sacubitril\/valsartan (S\/V) is an established therapy for heart failure that has been recently approved for hypertension in Japan. However, evidence regarding its use in combination with other antihypertensive agents in real-world practice is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe real-world prescribing patterns of S\/V among patients with hypertension in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study using a nationwide Japanese electronic health record database (August 2020 to October 2023) identified adults with hypertension (ICD-10: I10\u2013I15) who were newly prescribed S\/V. Patients with heart failure were excluded. Concomitant antihypertensive medications, S\/V dosing, and discontinuation patterns were assessed over 90 days following initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 9,486 patients (median age 79 years; 50.6% men), 63.6% received S\/V with a calcium channel blocker (CCB), 22.5% as monotherapy, and 11.8% as triple therapy with CCB and thiazide. At day 90, 55.5% of patients received S\/V plus a CCB, and 26.0% were on S\/V monotherapy. The S\/V discontinuation rate reached 11.8% by day 90. Approximately half of those on triple therapy discontinued the thiazide diuretic within 30 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Japanese patients with hypertension, S\/V is most commonly used in combination with a CCB, although a notable proportion receive it as monotherapy. These findings highlight the need for further studies to evaluate the safety, efficacy, and cost-effectiveness of S\/V-based combination regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1738988","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:44:19Z","timestamp":1784267059000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescription patterns of sacubitril\/valsartan among patients with hypertension in Japan"],"prefix":"10.3389","volume":"13","author":[{"given":"Aya F.","family":"Ozaki","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California","place":["Irvine, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanaga","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri T.","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Hospital","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Naqvi","sequence":"additional","affiliation":[{"name":"Mary & Steve Wen Cardiovascular Division, University of California Irvine Health","place":["Orange, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie T.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California","place":["Irvine, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kunitsu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jchf.2024.02.020","article-title":"Contemporary American and European guidelines for heart failure management: JACC: heart failure guideline comparison","volume":"12","author":"Ostrominski","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B2","year":""},{"key":"B3","year":""},{"key":"B4","doi-asserted-by":"publisher","first-page":"e14938","DOI":"10.1111\/jch.14938","article-title":"Efficacy and safety of sacubitril\/valsartan versus amlodipine in Japanese patients with essential hypertension: a randomized, multicenter, open-label, noninferiority study (PARASOL study)","volume":"27","author":"Yamamoto","year":"2025","journal-title":"J Clin Hypertens"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1738988\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:44:20Z","timestamp":1784267060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1738988\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":4,"alternative-id":["10.3389\/fcvm.2026.1738988"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1738988","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"article-number":"1738988"}}